![]() Cohort A of part 2 will be made up of patients with relapsed or refractory solid tumors with evidence of MYC amplification or overexpression. During part 2, patients will receive the recommended phase 2 dose. ![]() During part 1 of the open-label, randomized study, patients received escalating doses of KB-0742.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |